Genalyte Inc. has made available its rapid COVID-19 serology panel on its Maverick platform. The panel tests for the detection of IgG and IgM antibodies that the body produces in response to the novel coronavirus (SARS-CoV-2).
Genalyte’s U.S. Food and Drug Administration (FDA)-cleared Maverick Diagnostic System will expand antibody testing in the fight against COVID-19 with the launch of its SARS-CoV-2 Multi-Antigen Serology Panel.
